Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia

Trial Profile

Protocol 331-13-006: An Exploratory, Multicenter, Open-label, Monotherapy, Flexible-dose Brexpiprazole (OPC 34712) Trial in Adults With Early Episode Schizophrenia

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Mar 2016

At a glance

  • Drugs Brexpiprazole (Primary)
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 01 Sep 2015 Primary endpoint (PANSS Total Score change from baseline to Week 16) has been met, according to a results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology
    • 07 Dec 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top